{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:24:33Z","timestamp":1794003873090,"version":"4.8.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","award":["003\/2024"],"award-info":[{"award-number":["003\/2024"]}],"id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejca.2026.117763","type":"journal-article","created":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:18:35Z","timestamp":1791123515000},"page":"117763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Single-item measures of perceived side effect burden for people with cancer: A systematic scoping review"],"prefix":"10.1016","volume":"248","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4854-0968","authenticated-orcid":false,"given":"Tamara","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1797-6486","authenticated-orcid":false,"given":"Andreia Ferreira","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Alrjoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8422-8085","authenticated-orcid":false,"given":"Cecilie Delphin","family":"Amdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M.","family":"Giesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9142-1227","authenticated-orcid":false,"given":"Alexandra","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3153-780X","authenticated-orcid":false,"given":"Mogens","family":"Groenvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1074-2599","authenticated-orcid":false,"given":"Hayat","family":"Hamzeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9839-4532","authenticated-orcid":false,"given":"Zsuzsanna","family":"Iyizoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5252-6010","authenticated-orcid":false,"given":"Michael","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-2113","authenticated-orcid":false,"given":"Dagmara","family":"Kuli\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Lai-Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jammbe","family":"Musoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2531-0050","authenticated-orcid":false,"given":"Madeline","family":"Pe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3117-632X","authenticated-orcid":false,"given":"Morten Aa.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3635-8624","authenticated-orcid":false,"given":"Omar","family":"Shamieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1899-5942","authenticated-orcid":false,"given":"Galina","family":"Velikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8425-984X","authenticated-orcid":false,"given":"Florian","family":"Zeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Piccinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6185-9423","authenticated-orcid":false,"given":"Sandra","family":"Nolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejca.2026.117763_bib1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/jnci\/djr541","article-title":"Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review","volume":"104","author":"Howard-Anderson","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"issue":"16","key":"10.1016\/j.ejca.2026.117763_bib2","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.ejca.2010.06.010","article-title":"Quality of life among long-term (\u2a7e5years) colorectal cancer survivors \u2013 Systematic review.","volume":"46","author":"Jansen","year":"2010","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2026.117763_bib3","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/cncr.31133","article-title":"Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy","volume":"124","author":"Pearman","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2026.117763_bib4","first-page":"3613","article-title":"Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients","volume":"30","author":"Griffiths","year":"2022","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.117763_bib5","first-page":"37","article-title":"How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?","volume":"31","author":"Peipert","year":"2022","journal-title":"Support Care Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2026.117763_bib6","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s11136-024-03740-x","article-title":"The FACT-GP5 as a global tolerability measure: responsiveness and robustness to missing assessments","volume":"33","author":"Arizmendi","year":"2024","journal-title":"Qual Life Res"},{"issue":"3","key":"10.1016\/j.ejca.2026.117763_bib7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.23.00377","article-title":"Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial","volume":"42","author":"O'Connell","year":"2024","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2026.117763_bib8","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/jnci\/djp386","article-title":"Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes","volume":"101","author":"Basch","year":"2009","journal-title":"JNCI Journal National Cancer Institute"},{"issue":"11","key":"10.1016\/j.ejca.2026.117763_bib9","first-page":"2959","article-title":"Impact of oxaliplatin-induced neuropathy: a patient perspective","volume":"20","author":"Bennett","year":"2012","journal-title":"Support Care Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2026.117763_bib10","first-page":"802","article-title":"Symptom experience of patients undergoing treatment for multiple myeloma: a longitudinal real-world electronic patient-reported outcomes study","volume":"32","author":"Patel","year":"2024","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2026.117763_bib11","first-page":"371","article-title":"Real-world patient-reported outcomes and concordance between patient and physician reporting of side effects across lines of therapy in multiple myeloma within the USA","volume":"31","author":"Ribbands","year":"2023","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2026.117763_bib12","first-page":"3669","article-title":"The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review","volume":"24","author":"Atkinson","year":"2016","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2026.117763_bib13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1470-2045(25)00679-5","article-title":"Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial","volume":"27","author":"Wintner","year":"2026","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.117763_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s41687-022-00478-3","article-title":"An implementation study of electronic assessment of patient-reported outcomes in inpatient radiation oncology","volume":"6","author":"Nordhausen","year":"2022","journal-title":"J Patient Rep Outcomes"},{"issue":"7","key":"10.1016\/j.ejca.2026.117763_bib15","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2026.117763_bib16","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jval.2017.09.009","article-title":"Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop","volume":"21","author":"Kluetz","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.ejca.2026.117763_bib17","article-title":"Broadening the definition of tolerability in cancer clinical trials to capture the patient experience","author":"Basch","year":"2020","journal-title":"Friends Cancer Res"},{"key":"10.1016\/j.ejca.2026.117763_bib18","unstructured":"U.S. Food and Drug Administration, Core Patient-Reported Outcomes in Cancer Clinical Trials: Guidance for Industry. 2024."},{"key":"10.1016\/j.ejca.2026.117763_bib19","unstructured":"U.S. Food and Drug Administration, Core Patient-Reported Outcomes in Cancer Clinical Trials; Draft Guidance for Industry. 2021."},{"key":"10.1016\/j.ejca.2026.117763_bib20","unstructured":"European Organisation For Research And Treatment Of Cancer. EORTC Item Library. 2025; Available from: https:\/\/qol.eortc.org\/item-library\/."},{"issue":"3","key":"10.1016\/j.ejca.2026.117763_bib21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.117763_bib22","first-page":"939","article-title":"Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer","volume":"35","author":"Fitzsimmons","year":"1999","journal-title":"EORTC Study Group Qual Life Eur J Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2026.117763_bib23","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/bjc.2016.284","article-title":"Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder","volume":"115","author":"Kaupp-Roberts","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.117763_bib24","unstructured":"Piccinin, C., et al., EORTC Quality of Life Group Item Library User Guidelines. 2022. First Edition."},{"issue":"3","key":"10.1016\/j.ejca.2026.117763_bib25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1037\/0033-295X.84.3.231","article-title":"Telling more than we can know: Verbal reports on mental processes","volume":"84","author":"Nisbett","year":"1977","journal-title":"Psychol Rev"},{"issue":"10","key":"10.1016\/j.ejca.2026.117763_bib26","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters","year":"2020","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.ejca.2026.117763_bib27","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2026.117763_bib28","article-title":"Single-Item Measures of Side-Effect","volume":"2025","author":"Jones","year":"2025","journal-title":"Burd Oncol A Syst Scoping Rev"},{"issue":"10","key":"10.1016\/j.ejca.2026.117763_bib29","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1177\/1049732312452938","article-title":"Beyond PICO: the SPIDER tool for qualitative evidence synthesis","volume":"22","author":"Cooke","year":"2012","journal-title":"Qual Health Res"},{"key":"10.1016\/j.ejca.2026.117763_bib30","unstructured":"Veritas Health Innovation, Covidence systematic review software. 2025: Melbourne, Australia."},{"issue":"4","key":"10.1016\/j.ejca.2026.117763_bib31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjc.6606086","article-title":"Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21","volume":"104","author":"Friend","year":"2011","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2026.117763_bib32","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/cam4.385","article-title":"Development and validation of the functional assessment of cancer therapy-antiangiogenesis subscale","volume":"4","author":"Kaiser","year":"2015","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.ejca.2026.117763_bib33","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/oncolo\/oyad028","article-title":"Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19","volume":"28","author":"Bergerot","year":"2023","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ejca.2026.117763_bib34","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MLR.0b013e3181648e6e","article-title":"Comparability of interview- and self-administration of the Functional Assessment of Cancer Therapy-General (FACT-G) in English- and Spanish-speaking ambulatory cancer patients","volume":"46","author":"Hahn","year":"2008","journal-title":"Med Care"},{"issue":"9","key":"10.1016\/j.ejca.2026.117763_bib35","first-page":"575","article-title":"Validity of a single-item indicator of treatment side effect bother in patients with head and neck cancer","volume":"32","author":"Gharzai","year":"2024","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2026.117763_bib36","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ijrobp.2021.11.024","article-title":"Association Between Physician- and Patient-Reported Symptoms in Patients Treated With Definitive Radiation Therapy for Locally Advanced Lung Cancer in a Statewide Consortium","volume":"112","author":"Wilkie","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ejca.2026.117763_bib37","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3109\/10428194.2012.711830","article-title":"The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma","volume":"54","author":"Yost","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.ejca.2026.117763_bib38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s41687-024-00776-y","article-title":"Validity, reliability, responsiveness, and clinically meaningful change threshold estimates of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16)","volume":"8","author":"Clarke","year":"2024","journal-title":"J Patient Rep Outcomes"},{"issue":"2","key":"10.1016\/j.ejca.2026.117763_bib39","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s11482-022-10103-6","article-title":"Comparison of Simple-Summated Scoring and Toxicity Index Scoring of Symptom Bother in the NSABP B-30 Clinical Trial","volume":"18","author":"Hays","year":"2023","journal-title":"Appl Res Qual Life"},{"issue":"23","key":"10.1016\/j.ejca.2026.117763_bib40","doi-asserted-by":"crossref","first-page":"8884","DOI":"10.1002\/cam4.3506","article-title":"Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG-ACRIN Cancer Research Group (E1302)","volume":"9","author":"Oswald","year":"2020","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.ejca.2026.117763_bib41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cncr.35025","article-title":"Reliability, validity, and change thresholds of the NCCN\/FACT Bladder Symptom Index (NFBlSI-18) in patients with advanced urothelial cancer","volume":"130","author":"Peipert","year":"2024","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2026.117763_bib42","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.3854","article-title":"Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma","volume":"7","author":"Peipert","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.ejca.2026.117763_bib43","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1007\/s11136-024-03746-5","article-title":"Overall side effect assessment of oxaliplatin toxicity in rectal cancer patients in NRG oncology\/NSABP R04","volume":"33","author":"Peipert","year":"2024","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.ejca.2026.117763_bib44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s41687-024-00823-8","article-title":"Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer","volume":"8","author":"Regnault","year":"2024","journal-title":"J Patient Rep Outcomes"},{"issue":"12","key":"10.1016\/j.ejca.2026.117763_bib45","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jval.2018.04.1371","article-title":"Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma","volume":"21","author":"Cella","year":"2018","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.ejca.2026.117763_bib46","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/1740774520910389","article-title":"Exploration of baseline patient-reported side effect bother from cancer therapy","volume":"17","author":"Roydhouse","year":"2020","journal-title":"Clin Trials"},{"issue":"9","key":"10.1016\/j.ejca.2026.117763_bib47","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1007\/s11136-023-03426-w","article-title":"Psychometrics of patient-reported bother from side effects of treatment single-items in industry-sponsored oncology trials","volume":"32","author":"Trask","year":"2023","journal-title":"Qual Life Res"},{"issue":"3","key":"10.1016\/j.ejca.2026.117763_bib48","doi-asserted-by":"crossref","DOI":"10.2196\/18269","article-title":"Comparative Analysis of Paper-Based and Web-Based Versions of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16) Questionnaire in Breast Cancer Patients: Randomized Crossover Study","volume":"9","author":"Ma","year":"2021","journal-title":"JMIR Med Inform"},{"issue":"1","key":"10.1016\/j.ejca.2026.117763_bib49","doi-asserted-by":"crossref","DOI":"10.2196\/10004","article-title":"An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study","volume":"21","author":"Matthies","year":"2019","journal-title":"J Med Internet Res"},{"issue":"2","key":"10.1016\/j.ejca.2026.117763_bib50","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ygyno.2014.12.002","article-title":"Content validity of the NCCN-FACT ovarian symptom index-18 (NFOSI-18)","volume":"136","author":"Jensen","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.117763_bib51","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12955-019-1162-5","volume":"17","author":"Krohe","year":"2019","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"10.1016\/j.ejca.2026.117763_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2025.102304","article-title":"Assessing side-effect bother, burden, and tolerability: A qualitative study exploring the content validity of the Functional Assessment of Cancer Therapy - Item GP5","volume":"16","author":"Payakachat","year":"2025","journal-title":"J Geriatr Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2026.117763_bib53","first-page":"106","article-title":"Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.117763_bib54","unstructured":"National Cancer Institute. Overview of the PRO\u2011CTCAE. 2024 [cited 2026 February 4]; Available from: https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/overview.html."},{"issue":"6","key":"10.1016\/j.ejca.2026.117763_bib55","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/annonc\/mdx043","article-title":"Statistical controversies in clinical research: Value of adverse events relatedness to study treatment: analyses of data from randomized double-blind placebo-controlled clinical trials","volume":"28","author":"Le-Rademacher","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.117763_bib56","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926015455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926015455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:32:01Z","timestamp":1794000721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926015455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":56,"alternative-id":["S0959804926015455"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117763","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-item measures of perceived side effect burden for people with cancer: A systematic scoping review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117763"}}